Cyclobarbital

Cyclobarbital
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral (tablets)
ATC code	N05CA10 (WHO) ;
Legal status
Legal status	BR: Class B1 (Psychoactive drugs); CA: Schedule IV; DE: Anlage II (Authorized trade only, not prescriptible); UK: Class B; UN: Psychotropic Schedule III;
Pharmacokinetic data
Metabolism	Hepatic
Excretion	Renal
Identifiers
	IUPAC name 5-(1-cyclohexenyl)-5-ethyl-1,3-diazinane-2,4,6-trione;
CAS Number	52-31-3 ; calcium: 143-76-0 ;
PubChem CID	5838;
ChemSpider	5632 ;
UNII	0M8A98AD9H; calcium: 0HZN7FV25R ;
KEGG	D07323 ;
ChEMBL	ChEMBL268164 ;
CompTox Dashboard (EPA)	DTXSID9022865 ;
ECHA InfoCard	100.000.127
Chemical and physical data
Formula	C12H16N2O3
Molar mass	236.271 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1NC(=O)NC(=O)C1(/C2=C/CCCC2)CC;
	InChI InChI=1S/C12H16N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h6H,2-5,7H2,1H3,(H2,13,14,15,16,17) ; Key:WTYGAUXICFETTC-UHFFFAOYSA-N ;
	(what is this?) (verify)

Cyclobarbital, cyclobarbitol or cyclobarbitone refers to a barbiturate derivative developed in the early 1970s in the Soviet Union.^[2]

Quick Facts Clinical data, AHFS/Drugs.com ...

It was available in Russia until 2019, marketed and distributed as Reladorm, a fixed-dose combination pairing 100 mg cyclobarbital and 10 mg diazepam (a benzodiazepine anxiolytic, muscle relaxant, and anticonvulsant) indicated for treating insomnia before it was discontinued in 2019.

References